AGM 2018: Election of New Chairman and Board of Directors

SynDermix announces the election of a new Chairman and Board of Directors at the Annual General Meeting of 2018.



The management of SynDermix announced today the unanimous election of a new chairman and five new members of the Board of Directors at the Annual General Meeting of 2018. Joining the board are: Kevin P. Cox, Hans Peter Frick, Wolfgang Werlé, Hermann A. Wirz and Thomas Mehrling, also SynDermix’s newly appointed chairman. “On behalf of SynDermix, I am delighted to welcome Thomas, Kevin, Hans Peter, Wolfgang and Hermann to our Board of Directors,” said Dieter Hemmer, CEO. “They join SynDermix during a period of great momentum and I am confident that each will make an invaluable contribution toward helping us achieve our full potential as a global player in the biotech industry.” The board convened for its first meeting shortly after the AGM drew to a close. Addressing the new members of the board and the management of SynDermix at the end of the meeting, Thomas Mehrling stated: “It was very interesting and useful to get a glimpse of the dynamics in the various projects and it was also very impressive to see what was already achieved quite recently. I am very much looking forward to working with you all on the operations of SynDermix going forward and to help advance the company in the best interest of patients and the shareholders.”

SynDermix Board of Directors

SynDermix Board of Directors as of June 2018

About SynDermix AG
SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.

SynDermix has built a diversified portfolio of innovative assets which correspond to three distinct proprietary technology platforms: smart medical devices based on digital acoustic modulation; drugs and medical devices based on a topical nitric oxide-releasing formulation; and drug candidates based on a recombinant plant lectin. Its business model is to a large extent virtual, driven by a strategy of in-licensing, outsourcing and out-licensing; the Company enters into strategic partnerships with third parties for the acquisition, development and commercialisation of a robust portfolio of assets with high innovation value and commercial potential. For more information please visit:


SynDermix Management AG
Julian Heinrich

+41 44 366 40 16